Drug Trial News

RSS

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Study details challenges and progress toward creating a COVID-19 drug

The COVID-19 pandemic has seen scientists perform incredible feats in a short amount of time, from developing tests to new types of vaccines.

26 May 2021

Researchers to conduct Phase 1 gene therapy trial to treat Alzheimer's disease

The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.

26 May 2021

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

A team of scientists from Germany has recently evaluated the reactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently available on the medRxiv* preprint server.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Plant-based vaccine against SARS-CoV-2 shows promise

Researchers at Canadian biotechnology company Medicago report that Phase 1 trials of a plant-based vaccine for SARS-CoV-2 are underway and showing promise.

21 May 2021

Trial results show upadacitinib to be the most effective treatment for atopic dermatitis

The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021).

21 May 2021

Penn University more than doubles the percentage of Black patients in cancer clinical trials

A five-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania (ACC) to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group with historically low representation in cancer research.

21 May 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

20 May 2021

Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma

Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

Clinical trial looks at cannabis as a potentially effective treatment for acute migraines

Allison Knigge was in elementary school when she started to experience migraines. They continued to get progressively worse as time went on, especially after the birth of her son.

20 May 2021

Randomized clinical trials compare effects of coronary revascularization versus medical therapy alone

A rigorous meta-analysis of randomized clinical trials (RCTs) that compared the effects of medical therapies alone with medical therapies plus revascularization in patients with stable ischemic heart disease (SIHD) was presented at EuroPCR on May 18, 2021.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo

18 May 2021

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Previous
1
...
57
58
59
60
61
62
63
...
1149
Next

Drug Trial News

Study shows CoronaVac to have high seroconversion rate after 40 days

Study details challenges and progress toward creating a COVID-19 drug

Researchers to conduct Phase 1 gene therapy trial to treat Alzheimer's disease

Moderna's COVID vaccine proves effective against South African variant in primates

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

Do mixed COVID-19 vaccines provide immunity?

Plant-based vaccine against SARS-CoV-2 shows promise

Trial results show upadacitinib to be the most effective treatment for atopic dermatitis

Penn University more than doubles the percentage of Black patients in cancer clinical trials

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Clinical trial looks at cannabis as a potentially effective treatment for acute migraines

Randomized clinical trials compare effects of coronary revascularization versus medical therapy alone

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Pirfenidone significantly reduces a marker of heart muscle scarring

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News